Researchers at the Harvard Wyss Institute have developed a new type of cell therapy for multiple sclerosis patients. The technique involves taking a blood sample from the patient being treated, isolating a sample of…
Continue Reading
Adaptimmune and TCR2 Therapeutics, two clinical-stage biotechs that have recently cut staff to conserve capital, are coming together in a deal that aligns their cell therapy strategies. The business combination also extends the new…
Continue Reading
Chroma Medicine, a biotech company developing therapies that turn genes on or off as a way of treating genetic disorders, has raised $135 million as it works to generate data that could show the…
Continue Reading
Patients whose blood cancer advances after initial treatments have one last therapeutic option: the engineering of their immune cells into a living medicine. But cancer is crafty and it often finds a way to…
Continue Reading
There are so many challenges that we are currently facing in the world of healthcare, that possibly adding another one is overwhelming to think about. AI automation is still so new that it’s hard…
Continue Reading
A Fulcrum Therapeutics clinical trial testing a potential sickle cell disease drug has been paused by the FDA. With the clinical hold on the early-stage study, Fulcrum becomes the fourth company with a stalled…
Continue Reading
Imagine being unable to reach, throw, lift, push, or pull. That is how essential shoulders are to our daily function. It is one of the most complex and vital joints in the…
Continue Reading
Researchers at the Harvard Wyss Institute and the Dana-Farber Cancer Institute have developed a new method to prepare chimeric antigen receptor-T cells (CAR-T cells) for leukemia patients that could result in more effective treatment. CAR-T cells start life as T cells that are isolated from cancer patients, are stimulated and primed to recognize and attack cancer cells, expanded in number, and then reintroduced to the cancer patient with the goal that the cells will destroy their cancer. However, the technique works better in certain patients, and the researchers behind this latest technique have realized that T-cells from cancer patients do […]…
Continue Reading
Talaris Therapeutics aimed to transform solid organ transplants with a cell therapy that replaces anti-rejection drugs patients need for the rest of their lives. But after clinical trial setbacks, the biotech has decided to end two kidney transplant studies. Although a separate test of its experimental therapy is continuing in a rare autoimmune condition, Talaris has commenced a restructuring plan that it said could culminate in a merger or sale of the company.
The restructuring announced Thursday will lead to the layoff of about one-third of Talaris’s staff. As of the end of the third quarter of 2022, the Louisville, Kentucky-based biotech…
A slew of biotech companies are pursuing research that could overcome limitations of current cell therapies. Startup creator Replay has a new subsidiary pushing toward the front of the pack with a therapeutic candidate on track to start its first human test this summer—about one year after Replay emerged from stealth. It owes this rapid progress to a cell therapy pioneer’s technology that has already been de-risked by a big pharmaceutical company.
Replay calls itself a genome writing company. With operations split between San Diego and London, the private equity-backed business launched last July with $55 million and a suite of technologies…
